<DOC>
	<DOCNO>NCT00515034</DOCNO>
	<brief_summary>The purpose study assess safety tolerability doripenem compare imipenem Ventilator-assisted pneumonia complicate Intra-abdominal Infection . The study population include hospitalize patient ( patient resident chronic health care facility ) diagnosis either Ventilator associate pneumonia complicate Intra-abdominal Infection .</brief_summary>
	<brief_title>A Safety Tolerability Study Doripenem Patients With Abdominal Infections Pneumonia</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , open-label ( people involve know identity intervention ) , multicenter study evaluate safety tolerability doripenem ( antibiotic use treat infection ) patient ventilator-associated pneumonia ( VAP ) complicate intra-abdominal infection ( cIAI ) . Approximately 250 patient assign 3:1 ratio receive doripenem imipenem/cilastatin ( 188 patient randomized receive doripenem 62 patient randomized receive imipenem/cilastatin ) . Furthermore , patient receive doripenem imipenem/cilastatin stratify disease ( VAP cIAI ) . Therefore , report purpose , 4 group : Patients VAP treat doripenem , patient VAP treat imipenem/cilastatin , patient cIAI treat doripenem , patient cIAI treat imipenem/cilastatin . Study drug administer intravenously ( iv ) ( vein ) 7 14 day patient VAP 5 14 day patient cIAI . The maximum duration study drug 14 day . Vancomycin and/or amikacin may add study drug regimen adjunctive therapy patient meet study specify criterion . The recommended dosage vancomycin 1 g every 12 hour administer iv infusion . The addition amikacin discretion investigator patient VAP ( cIAI ) recommend dose regimen amikacin 15 mg/kg give iv day . Alternative amikacin regimen aminoglycoside regimen may permit . Safety assess study monitor adverse event , evaluation laboratory test result , change vital sign . The primary endpoint study ass overall incidence treatment-emergent adverse event ( TEAEs ) initiation first infusion study drug 30 day completion study drug therapy . Treatment-emergent adverse event define adverse event occur worsen initial infusion study drug 30 day last dose study drug . The hypothesis study doripenem similar safety profile imipenem . Doripenem ( 1g 8-hour interval period 4 hour ) imipenem/cilastatin ( 1g 8-hours period 1 hour ) administer intravenous ( iv ) infusion ( delivery drug slowly vein period time ) . Patients diagnose ventilator associate pneumonia ( VAP ) treat 7 14 day patient complicate intra-abdominal infection ( cIAI ) treat 5 14 day .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Abdominal Abscess</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<mesh_term>Cilastatin</mesh_term>
	<criteria>Patients must hospitalize diagnosis VentilatorAssisted Pneumonia ( VAP ) complicate IntraAbdominal Infection ( cIAI ) Patients VAP must hospitalize ( chronic care facility ) &gt; = 5 day , receive mechanical ventilation &gt; = 48 hour , Clinical Pulmonary Infection Score ( CPIS ) &gt; = 5 , new progressive radiographic infiltrates ( relate another disease process ) Patients cIAI must clinical evidence intraabdominal infection , abdominal pain tenderness , localize diffuse abdominal wall rigidity , mass , ileus requirement surgical intervention ( e.g. , laparotomy , laparoscopic surgery , percutaneous drain abscess ) within 24 hour study entry Patients history acute hepatic failure acute decompensation chronic hepatic failure , history severe impairment renal function , history immunocompromising illness , acquire immunodeficiency syndrome ( AIDS ) , human immunodeficiency virus ( HIV ) CD4 count le 200 cells/mL within past 6 month organ ( include bone marrow ) transplant recipient hematologic malignancy use immunosuppressive therapy screening , include use high dose corticosteroid ( e.g. , &gt; 40 mg prednisone equivalent per day &gt; 2 week ) history rapidly progress disease immediately lifethreatening illness ( include acute hepatic failure septic shock )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Doripenem</keyword>
	<keyword>Imipenem</keyword>
	<keyword>Cilastatin</keyword>
	<keyword>Vancomycin</keyword>
	<keyword>DORIBAX , DORIPREX , FINIBAX , DURAPTA , PRIMAXIN , Anti Bacterial Agents</keyword>
	<keyword>Ileus</keyword>
	<keyword>Hospitalized</keyword>
	<keyword>Fever</keyword>
</DOC>